Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Edgewise Therapeutics, Inc. Director's Dealing 2021

Mar 26, 2021

31829_dirs_2021-03-25_98849686-1694-475e-a8cb-8352355507b5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25

Reporting Person: Russell Alan J (Director, Chief Scientific Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 264100 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $0.18 2032-06-27 Common Stock (1531780) Direct
Stock Option (Right to Buy) $0.18 2027-08-08 Common Stock (147585) Direct
Stock Option (Right to Buy) $0.45 2028-08-30 Common Stock (155352) Direct
Stock Option (Right to Buy) $0.64 2029-11-14 Common Stock (227332) Direct
Stock Option (Right to Buy) $0.71 2030-09-01 Common Stock (190137) Direct
Stock Option (Right to Buy) $1.93 2030-12-15 Common Stock (475183) Direct

Footnotes

F1: 1/48th of the shares subject to the option became vested and exercisable on July 27, 2017 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

F2: 1/4th of the shares subject to the option became vested and exercisable on July 27, 2018 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

F3: 1/48th of the shares subject to the option became vested and exercisable on September 10, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

F4: 1/48th of the shares subject to the option became vested and exercisable on November 16, 2019 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

F5: 1/48th of the shares subject to the option became vested and exercisable on October 2, 2020 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

F6: 1/48th of the shares subject to the option became vested and exercisable on January 30, 2021 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.